Presentation is loading. Please wait.

Presentation is loading. Please wait.

Tezepelumab, an anti–thymic stromal lymphopoietin monoclonal antibody, in the treatment of moderate to severe atopic dermatitis: A randomized phase 2a.

Published byΠρίσκα Βαρνακιώτης Modified over 5 years ago

Similar presentations

Presentation on theme: "Tezepelumab, an anti–thymic stromal lymphopoietin monoclonal antibody, in the treatment of moderate to severe atopic dermatitis: A randomized phase 2a."— Presentation transcript:

1 Tezepelumab, an anti–thymic stromal lymphopoietin monoclonal antibody, in the treatment of moderate to severe atopic dermatitis: A randomized phase 2a clinical trial  Eric L. Simpson, MD, Jane R. Parnes, MD, Dewei She, PhD, Sarah Crouch, BA (Hons), William Rees, PhD, May Mo, MS, René van der Merwe, MBChB  Journal of the American Academy of Dermatology  Volume 80, Issue 4, Pages (April 2019) DOI: /j.jaad Copyright © 2018 American Academy of Dermatology, Inc. Terms and Conditions

2 Fig 1 Patient disposition. TCS, Topical corticosteroids.
Journal of the American Academy of Dermatology  , DOI: ( /j.jaad ) Copyright © 2018 American Academy of Dermatology, Inc. Terms and Conditions

3 Fig 2 A, Percentage of patients who achieved EASI50, EASI75, and EASI90 responses at weeks 12 and 16. B, Percentage improvement from baseline in EASI (total score) over time. C, Percentage of patients with an IGA response at weeks 12 and 16. D, Percentage improvement from baseline in SCORAD (total score) over time. Analyses conducted in the ITT population. Patients were considered to be IGA responders if they had an IGA response of 0 or 1 and a reduction of ≥2 grades from baseline to week 12. IGA severity categories are 0 (clear), 1 (almost clear), 2 (mild), 3 (moderate), 4 (severe), and 5 (very severe). *Nominal P < .05 for the comparison with placebo. EASI50, A ≥50% reduction in Eczema Area and Severity Index score; EASI75, a ≥75% reduction in Eczema Area and Severity Index score; EASI90, a ≥90% reduction in Eczema Area and Severity Index score; IGA, Investigator's Global Assessment; ITT, intention-to-treat; SCORAD, Scoring of Atopic Dermatitis; SE, standard error; TCS, topical corticosteroids. Journal of the American Academy of Dermatology  , DOI: ( /j.jaad ) Copyright © 2018 American Academy of Dermatology, Inc. Terms and Conditions

4 Fig 3 Percentage improvement from baseline in pruritus NRS for the ITT population. *Nominal P < .05 for the comparison with placebo. ITT, Intention-to-treat; NRS, numerical rating scale; SE, standard error; TCS, topical corticosteroids. Journal of the American Academy of Dermatology  , DOI: ( /j.jaad ) Copyright © 2018 American Academy of Dermatology, Inc. Terms and Conditions

Download ppt "Tezepelumab, an anti–thymic stromal lymphopoietin monoclonal antibody, in the treatment of moderate to severe atopic dermatitis: A randomized phase 2a."

Similar presentations

Serum vitamin D status in adult patients with atopic dermatitis: Recommendations for daily practice  Jorien van der Schaft, MD, PhD, Lieneke F.M. Ariens,

Serum vitamin D status in adult patients with atopic dermatitis: Recommendations for daily practice  Jorien van der Schaft, MD, PhD, Lieneke F.M. Ariens,
The effect of secukinumab on moderate-to-severe scalp psoriasis: Results of a 24- week, randomized, double-blind, placebo-controlled phase 3b study  Jerry.

The effect of secukinumab on moderate-to-severe scalp psoriasis: Results of a 24- week, randomized, double-blind, placebo-controlled phase 3b study  Jerry.
Secukinumab sustains early patient-reported outcome benefits through 1 year: Results from 2 phase III randomized placebo-controlled clinical trials comparing.

Secukinumab sustains early patient-reported outcome benefits through 1 year: Results from 2 phase III randomized placebo-controlled clinical trials comparing.
A randomized study of the efficacy and safety of injectable poly-L-lactic acid versus human-based collagen implant in the treatment of nasolabial fold.

A randomized study of the efficacy and safety of injectable poly-L-lactic acid versus human-based collagen implant in the treatment of nasolabial fold.
Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial  Diamant.

Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial  Diamant.
Lauren Kwa, BA, Jonathan I. Silverberg, MD, PhD, MPH 

Lauren Kwa, BA, Jonathan I. Silverberg, MD, PhD, MPH 
Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to- severe plaque psoriasis up to 1 year: Results from the CLEAR study 

Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to- severe plaque psoriasis up to 1 year: Results from the CLEAR study 
ATX-101 for reduction of submental fat: A phase III randomized controlled trial  Shannon Humphrey, MD, Jonathan Sykes, MD, Jonathan Kantor, MD, MSCE, MA,

ATX-101 for reduction of submental fat: A phase III randomized controlled trial  Shannon Humphrey, MD, Jonathan Sykes, MD, Jonathan Kantor, MD, MSCE, MA,
Yul W. Yang, MD, PhD, David J. DiCaudo, MD 

Yul W. Yang, MD, PhD, David J. DiCaudo, MD 
Volume 10, Issue 7, Pages (July 2018)

Volume 10, Issue 7, Pages (July 2018)
Efficacy and safety of fezakinumab (an IL-22 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by conventional.

Efficacy and safety of fezakinumab (an IL-22 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by conventional.
Treatment of atopic dermatitis with tralokinumab, an anti–IL-13 mAb

Treatment of atopic dermatitis with tralokinumab, an anti–IL-13 mAb
ATX-101 for reduction of submental fat: A phase III randomized controlled trial  Shannon Humphrey, MD, Jonathan Sykes, MD, Jonathan Kantor, MD, MSCE, MA,

ATX-101 for reduction of submental fat: A phase III randomized controlled trial  Shannon Humphrey, MD, Jonathan Sykes, MD, Jonathan Kantor, MD, MSCE, MA,
Serum leptin and adiponectin levels in atopic dermatitis (AD) and their relation to disease severity  Byeol Han, MD, Wen Hao Wu, PhD, Jung Min Bae, MD,

Serum leptin and adiponectin levels in atopic dermatitis (AD) and their relation to disease severity  Byeol Han, MD, Wen Hao Wu, PhD, Jung Min Bae, MD,
Elana Putterman, BS, Leslie Castelo-Soccio, MD, PhD 

Elana Putterman, BS, Leslie Castelo-Soccio, MD, PhD 
Shawn G. Kwatra, BS, Hong Liang Tey, MRCP (UK), Saba M

Shawn G. Kwatra, BS, Hong Liang Tey, MRCP (UK), Saba M
Serum vitamin D status in adult patients with atopic dermatitis: Recommendations for daily practice  Jorien van der Schaft, MD, PhD, Lieneke F.M. Ariens,

Serum vitamin D status in adult patients with atopic dermatitis: Recommendations for daily practice  Jorien van der Schaft, MD, PhD, Lieneke F.M. Ariens,
Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to.

Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to.
OPA-15406, a novel, topical, nonsteroidal, selective phosphodiesterase-4 (PDE4) inhibitor, in the treatment of adult and adolescent patients with mild.

OPA-15406, a novel, topical, nonsteroidal, selective phosphodiesterase-4 (PDE4) inhibitor, in the treatment of adult and adolescent patients with mild.
Two randomized, double-blind, placebo-controlled studies of fluticasone propionate lotion 0.05% for the treatment of atopic dermatitis in subjects from.

Two randomized, double-blind, placebo-controlled studies of fluticasone propionate lotion 0.05% for the treatment of atopic dermatitis in subjects from.

Similar presentations

Ads by Google